Why the Citadel share price is racing higher on Monday

The Citadel Group Ltd (ASX:CGL) share price has been a strong performer on the All Ordinaries on Monday. Here's why it is racing higher…

a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The market may have dropped lower today, but that hasn't stopped the Citadel Group Ltd (ASX: CGL) share price from charging higher.

In afternoon trade the managed technology solutions provider's shares are up 4% to $4.98.

Why is the Citadel share price racing higher?

Investors have been buying the company's shares on Monday after it provided an update on recent contract wins.

This afternoon Citadel announced that the Department of Defence has elected to exercise both its extension options. This means its will be taking the company's support contract through to July 2021.

In addition to this, Citadel advised that it expects the Department of Defence to issue a new tender or similar process for the longer-term sustainment contract. This is a process in which Citadel intends to participate.

Citadel's CEO, Mark McConnell, said: "We are very pleased to be awarded the two contract extensions by the Department of Defence, reflecting the quality work that Citadel has delivered to the Department over many years. This news comes on the back of other recent material contract extensions, including the 10- year contract extension for Enterprise Pathology Software for Queensland Health announced on 13 December 2019."

Citadel Health.

The company also revealed that its Citadel Health business has secured a new contract.

Following the announcement at its AGM of Citadel's preferred supplier status to manage and support the Melbourne Genomics Alliance systems (Genovic), Citadel has now moved to a full contract valued at approximately $500,000 for the initial stages of work.

There are options to extend to contract for a further 3 years following further client funding approval.

Genovic is an alliance of 10 leading healthcare and research organisations that are committed to improving patient outcomes via the rapid identification of cancer and disease symptoms.

Citadel Health will initially be responsible for managing the Genovic platform, help desk, application and integration testing, change management and client onboarding.

Also rising strongly on Monday despite the market weakness were the shares of Medical Developments International Ltd (ASX: MVP) and Pro Medicus Limited (ASX: PME). They are up 7.5% and 4.5%, respectively, in late trade on the back of no news.

James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of Medical Developments International Limited. The Motley Fool Australia's parent company Motley Fool Holdings Inc. recommends Pro Medicus Ltd. The Motley Fool Australia owns shares of and has recommended Pro Medicus Ltd. The Motley Fool Australia has recommended Citadel Group Ltd and Medical Developments International Limited. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Gainers

Stock market chart in green with a rising arrow symbolising a rising share price.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a massive day for the ASX 200, with a new all-time high recorded.

Read more »

A man sits thoughtfully on the couch with a laptop on his lap.
Technology Shares

This ASX tech stock rocketed 60% in March! Can it keep on delivering?

After soaring in March, the ASX tech stock is now up 169% since this time last year.

Read more »

A young women pumps her fists in excitement after seeing some good news on her laptop.
Share Gainers

Why Mesoblast, Newmont, Pilbara Minerals, and Platinum shares are jumping

These ASX shares are ending the week strongly. But why?

Read more »

A young male ASX investor raises his clenched fists in excitement because of rising ASX share prices today
Share Gainers

3 ASX All Ords shares up 50%+ in March

These ASX shares have been on fire this month. But why?

Read more »

Woman looks amazed and shocked as she looks at her laptop.
Share Gainers

Why Mesoblast, Patriot Battery Metals, Sigma, and Zip shares are pushing higher

These shares are having a good session on hump day. But why?

Read more »

Woman looks amazed and shocked as she looks at her laptop.
Consumer Staples & Discretionary Shares

If you'd put $20,000 in this ASX retail stock at the start of 2023, you'd have $134,000 now

This online retailer has executed a remarkable turnaround for its investors.

Read more »

Fancy font saying top ten surrounded by gold leaf set against a dark background of glittering stars.
Share Gainers

Here are the top 10 ASX 200 shares today

It was back to earth for ASX shares this Tuesday.

Read more »

Two happy scientists analysing test results.
Healthcare Shares

Mesoblast share price rockets 36% on breaking FDA news

ASX investors are sending the Mesoblast share price soaring following promising FDA news.

Read more »